SynthesisFrontiers in microbiology2025
The oncogenic role of human papillomavirus in breast cancer: a comprehensive systematic review and meta-analysis.
Synthesis in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HPV DNA Detection and Genotyping in Basal-Like Breast Carcinoma: Insights into a Possible Viral Association.Diagnostics (Basel, Switzerland) · 2026Article
- Unveiling the inhibitory effects of tannic acid and doxorubicin combination on pyruvate kinase M2 in breast cancer cells.Frontiers in pharmacology · 2026Article
- Transcriptional modulation of the PI3K/AKT/mTOR signaling pathway mediated by HPV16Exploration of targeted anti-tumor therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human papillomavirus (HPV) has been increasingly implicated in the pathogenesis of breast cancer (BC), though its role remains controversial. Understanding HPV prevalence and genotype distribution across histological types and regions may clarify this potential association. Methods: A comprehensive systematic review and meta-analysis was conducted using PubMed, Scopus, and Web of Science databases for studies published between January 1990 and April 2025. Eligible studies reported HPV prevalence in BC tissues stratified by histological classification. Non-English studies, reviews, and those lacking histological stratification were excluded. Data from 49 studies encompassing 4,173 BC cases were extracted. Pooled HPV prevalence and odds ratios (ORs) were calculated using random-effects models. Subgroup analyses were performed by histology, geographic region, and HPV genotype (16/18). Risk of bias was assessed using the Joanna Briggs Institute (JBI) checklist for cross-sectional studies and the Newcastle-Ottawa Scale for case-control designs. Results: The pooled prevalence of HPV in BC tissues was 23% (95% CI: 18-28%), highest in invasive ductal carcinoma (24%). HPV-positive individuals exhibited a 3.6-fold higher risk of developing BC (OR = 3.63, 95% CI: 2.33-5.64), with the strongest association in invasive lobular carcinoma (OR = 4.41). HPV-18 showed a more consistent correlation with BC than HPV-16. Regional variation was observed, with Asian populations showing higher HPV prevalence and stronger associations. Discussion: This meta-analysis suggests a significant association between HPV infection-particularly genotype 18-and breast cancer risk, especially in Asian regions and specific histological subtypes. These findings highlight the need for mechanistic studies and standardized molecular detection to elucidate the potential oncogenic role of HPV in breast tissue. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=1051960 identifier CRD420251051960.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.